Samjin Pharmaceutical Co., Ltd.

Incheon University Industry Academic Cooperation Foundation

Bamichem Co., Ltd.

Astech. Co., Ltd.

Incheon National University Research & Business Foundation

Ho Seok Kwon

Hyun Tae Kim

Hee Jong Shin

Jae Woong Lee

Eui Hwan Cho

Jeong Ho Joo

Jong Min Kim

Sung Pyo Hong

Sung Woo Lee

Eui-Hwan Cho

Soon Kil Ahn

Min Hyo Ki

Woo Heon Song

Sung Ju Choi

Ki Seok Park

Jong Bae Yoon

Ho Tae Nam

Sung Hyun Kang

Ho Joon Park

Yong Bin Park

Young Hun Lee

Keun Kuk Lee

Sung Hye Kim

Hyoung Min Cho

Woo-Heon Song

Eunsun Song

Kug Hwa Lee

Typeface

Disclosed are a novel rebamipide prodrug, a method for preparing the same, and use thereof. Also, a pharmaceutical composition comprising the novel rebamipide prodrug as an active ingredient is provided. The rebamipide prodrug is increased 25-fold in absorption rate compared to rebamipide itself, and can be applied to the prophylaxis or therapy of gastric ulcer, acute gastritis, chronic gastritis, xerophthalmia, cancer, osteoarthritis, rheumatoid arthritis, or obesity.

Rebamipide prodrugs, preparation method and use thereof

The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.

Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof

Growing community of inventors

Gyeonggi-do, South Korea

Ho Seok Kwon